As of June 12, 2025, Adamis Pharmaceuticals Corp (ADMP) reports a ROE (Return on Equity) of 4073.85%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Adamis Pharmaceuticals Corp's ROE (Return on Equity)
Over recent years, Adamis Pharmaceuticals Corp's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | 4073.85% |
| 2021-12-31 | -177.09% |
| 2020-12-31 | -1411.14% |
| 2019-12-31 | -83.36% |
| 2018-12-31 | -83.55% |
This slight upward trend highlights how Adamis Pharmaceuticals Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Adamis Pharmaceuticals Corp's ROE (Return on Equity) to Peers
To better understand Adamis Pharmaceuticals Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Adamis Pharmaceuticals Corp (ADMP) | 4073.85% |
| BellRock Brands Inc (BRCK.U.CN) | 781.79% |
| Slang Worldwide Inc (SLNG.CN) | 442.19% |
| Eyenovia Inc (EYEN) | 380.41% |
| Body and Mind Inc (BAMM.CN) | 204.64% |
| Eli Lilly and Co (LLY) | 74.62% |
Compared to its competitors, Adamis Pharmaceuticals Corp's ROE (Return on Equity) is higher than all peers, suggesting efficient use of shareholder equity to generate profits.